With a $45 million grant from the National Institutes of Health and National Institute on Aging, the Alzheimer’s Disease Cooperative Study (ADCS) at University of California San Diego, in collaboration with Burke Neurological Institute (BNI) and Columbia University Irving Medical Center, will launch a nationwide clinical trial to further investigate the therapeutic potential of benfotiamine, a synthetic version of thiamine (B1), as a metabolic treatment approach to Alzheimer’s disease.
A novel, disease-modifying therapy for Alzheimer’s disease may involve the whole exchange of blood, which effectively decreased the formation of amyloid plaque in the brains of mice, according to a new study from UTHealth Houston.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia, affecting more than 5.8 million individuals in the U.S.
A new mouse study reveals a breakdown in the process that clears brain cells of waste products precedes the buildup of amyloid plaques associated with Alzheimer’s disease.
QUT genetic researchers have found blood proteins that cause migraine and have a shared link with Alzheimer’s disease that could potentially be prevented by repurposing existing therapeutics.
Alzheimer’s disease (AD), the most common type of dementia, progressively impairs memory, concentration and the ability to learn new things and accomplish everyday activities. Although scientists do not yet fully understand the causes of cognitive impairment associated with AD, a group of researchers at Baylor College of Medicine has discovered that type I interferon (IFN), an inflammation-eliciting molecule abnormally produced in the AD brain, is a major driver of memory and cognitive loss in a mouse model of the disease. Importantly, blocking IFN reversed these memory and cognitive deficits in the animal model.